BC Week In Review | Jun 15, 2018
Financial News

Aivita raises $15M series B, considers Korean clinical trial for cancer therapy

Cellular therapy company Aivita Biomedical Inc. (Irvine, Calif.) raised $15 million on June 11 in a series B round led by sole South Korean investor SFC Co. Ltd. (KOSDAQ:112240). The round gives it a cash...
BC Week In Review | May 25, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BC Extra | May 18, 2018
Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
BioCentury | Mar 10, 2018
Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
BC Week In Review | Jul 6, 2017
Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global...
BC Extra | Jun 30, 2017
Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
BC Innovations | May 11, 2017
Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
BC Week In Review | Feb 8, 2017
Clinical News

DCVax-L: Ph III ongoing

Northwest Biotherapeutics said FDA lifted the partial clinical hold on a double-blind, placebo-controlled, international Phase III trial evaluating intradermal DCVax-L given at days 0, 10 and 20 and weeks 8, 16, 32, 48, 72, 96...
BC Week In Review | Jan 13, 2017
Company News

Valeant, Sanpower deal

Valeant is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower for $819.9 million in cash. Valeant expects the deal to close next quarter. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global rights to...
BC Extra | Jan 10, 2017
Company News

Valeant selling Dendreon to Chinese conglomerate

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower Group Co. Ltd. (Nanjing, China) for $819.9 million in cash. Valeant expects the deal to close this half. In February...
Items per page:
1 - 10 of 154